Pancreatic Cancer Research

ResearcherUniversity of TurinActive in the last 2 years

Monica Argenziano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8485-7460; OpenAlex author ID A5022822406. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2025: 1 paper · 2026: 2 papers

Papers 3

  1. The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma. First author DOI 10.1016/j.biopha.2026.119956↗
  2. Erratum to "Gemcitabine-loaded ICOS-Fc decorated nanosponges: a new chemo immunotherapy combination against pancreatic cancer". [Int. J. Pharm. 682 (2025) 1258… Co-author DOI 10.1016/j.ijpharm.2026.126582↗
  3. Gemcitabine-loaded ICOS-Fc decorated nanosponges: A new chemo immunotherapy combination against pancreatic cancer. Co-author DOI 10.1016/j.ijpharm.2025.125869↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stefania Pizzimenti · 2 shared papers, 2025–2026 · strength 0.52
  2. Chiara Dianzani · 2 shared papers, 2025–2026 · strength 0.52
  3. Davide Busato · 1 shared paper, 2026 · strength 0.24
  4. Michele Dal Bo · 1 shared paper, 2026 · strength 0.24
  5. Giuseppe Toffoli · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.